神经内分泌肿瘤治疗的演进。
Evolution of Neuroendocrine Tumor Therapy.
机构信息
Division of Endocrinology, University of Iowa Hospitals and Clinics, Room E401-5 GH, 200 Hawkins Drive, Iowa City, Iowa 52242, USA.
Department of Medicine, Division of Endocrinology and Metabolism, New York University Langone School of Medicine, New York, New York, 10016, USA.
出版信息
Surg Oncol Clin N Am. 2020 Apr;29(2):145-163. doi: 10.1016/j.soc.2019.11.002.
Abstract
To better understand developments in treatment of neuroendocrine tumors of the gastroenteropancreatic system, and the pivotal roles of native somatostatin and its long-acting analogues play in normal peptide regulation and neuropeptide excess associated with neuroendocrine tumors (NETs), this article delineates and defines distinct eras in the history and discovery of gastrointestinal endocrinology. We highlight the collaboration between academia and industry in basic science and the clinical research that advanced Lu-177-DOTATATE to approval as standard of care therapy for low-grade NETs. Examples of new radioisotopes and therapy compounds currently in development for diagnosis and therapy for high-grade NETs are also discussed.
摘要
为了更好地了解胃肠胰神经内分泌肿瘤治疗方面的进展，以及天然生长抑素及其长效类似物在正常肽调节和神经内分泌肿瘤（NETs）相关神经肽过度分泌中所起的关键作用，本文描述和定义了胃肠内分泌学历史和发现的不同时代。我们强调了学术界和工业界在基础科学和临床研究方面的合作，这些合作推动了 Lu-177-DOTATATE 被批准为低级别 NETs 的标准治疗方法。还讨论了目前正在开发用于高级别 NETs 诊断和治疗的新型放射性同位素和治疗化合物的实例。
相似文献
1
Evolution of Neuroendocrine Tumor Therapy.
Surg Oncol Clin N Am. 2020 Apr;29(2):145-163. doi: 10.1016/j.soc.2019.11.002.
2
Radionuclide Therapy for Neuroendocrine Tumors.
Curr Oncol Rep. 2017 Feb;19(2):9. doi: 10.1007/s11912-017-0567-8.
3
[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.
4
Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.
Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1023-1031. doi: 10.1080/17474124.2019.1685381. Epub 2019 Oct 30.
5
Neuroendocrine Tumor Therapy: Lu-DOTATATE.
AJR Am J Roentgenol. 2018 Aug;211(2):278-285. doi: 10.2214/AJR.18.19953. Epub 2018 Jun 27.
6
Effectiveness of radiolabelled somatostatin analogues (Y-DOTATOC and Lu-DOTATATE) in patients with metastatic neuroendocrine tumours: a single centre experience in Mexico.
Rev Esp Med Nucl Imagen Mol. 2017 May-Jun;36(3):166-174. doi: 10.1016/j.remn.2016.09.005. Epub 2016 Nov 24.
7
Lutetium oxodotreotide (Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.
BMC Cancer. 2021 Jan 5;21(1):10. doi: 10.1186/s12885-020-07710-7.
8
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.
Front Endocrinol (Lausanne). 2021 Apr 15;12:676973. doi: 10.3389/fendo.2021.676973. eCollection 2021.
9
Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
AJR Am J Roentgenol. 2021 Aug;217(2):495-506. doi: 10.2214/AJR.20.23349. Epub 2021 Jun 2.
10
Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors.
J Nucl Med. 2021 Nov;62(11):1558-1563. doi: 10.2967/jnumed.120.258772. Epub 2021 Feb 26.
引用本文的文献
1
Rare Head and Neck Neuroendocrine Neoplasms: A Retrospective Study of Prognosis and Treatment Outcomes.
Cancer Diagn Progn. 2025 Jun 30;5(4):469-477. doi: 10.21873/cdp.10460. eCollection 2025 Jul-Aug.
2
Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms.
Sci Rep. 2025 Apr 17;15(1):13356. doi: 10.1038/s41598-025-98588-7.
3
Improving neuroendocrine tumor treatments with mathematical modeling: lessons from other endocrine cancers.
Endocr Oncol. 2025 Feb 5;5(1):e240025. doi: 10.1530/EO-24-0025. eCollection 2025 Jan.
4
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations.
Endocr Oncol. 2024 Dec 19;4(1):e240055. doi: 10.1530/EO-24-0055. eCollection 2024 Jan 1.
5
Primary intraspinal neuroendocrine tumor: A case report and literature review.
Medicine (Baltimore). 2024 Aug 9;103(32):e39196. doi: 10.1097/MD.0000000000039196.
6
Risk factors for positive resection margins after endoscopic resection for gastrointestinal neuroendocrine tumors.
Surg Endosc. 2024 Apr;38(4):2041-2049. doi: 10.1007/s00464-024-10706-0. Epub 2024 Mar 1.
7
Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Cancers (Basel). 2023 Mar 20;15(6):1861. doi: 10.3390/cancers15061861.
8
Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives.
Front Oncol. 2022 May 25;12:848485. doi: 10.3389/fonc.2022.848485. eCollection 2022.
9
Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Pancreas. 2020 May/Jun;49(5):599-603. doi: 10.1097/MPA.0000000000001546.
本文引用的文献
1
Lutathera: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.
Pharmaceuticals (Basel). 2019 Jul 29;12(3):114. doi: 10.3390/ph12030114.
2
Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
Surgery. 2019 Jan;165(1):166-175. doi: 10.1016/j.surg.2018.04.070. Epub 2018 Oct 19.
3
The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018.
Endocrinol Metab Clin North Am. 2018 Sep;47(3):711-731. doi: 10.1016/j.ecl.2018.05.003.
4
The Origin and Understanding of the Incretin Concept.
Front Endocrinol (Lausanne). 2018 Jul 16;9:387. doi: 10.3389/fendo.2018.00387. eCollection 2018.
5
Agonist-induced CXCR4 and CB2 Heterodimerization Inhibits Gα13/RhoA-mediated Migration.
Mol Cancer Res. 2018 Apr;16(4):728-739. doi: 10.1158/1541-7786.MCR-16-0481. Epub 2018 Jan 12.
6
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.
Theranostics. 2018 Jan 1;8(2):369-383. doi: 10.7150/thno.21397. eCollection 2018.
7
The Changing Concept of Gut Endocrinology.
Endocr Dev. 2017;32:8-19. doi: 10.1159/000475728. Epub 2017 Aug 15.
8
Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine.
J Nucl Med. 2017 Sep;58(Suppl 2):3S-9S. doi: 10.2967/jnumed.116.186502.
9
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
PLoS One. 2017 Jul 21;12(7):e0181473. doi: 10.1371/journal.pone.0181473. eCollection 2017.
10
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.
Theranostics. 2017 Apr 8;7(6):1589-1597. doi: 10.7150/thno.19050. eCollection 2017.
Zotero 插件